Congenital Thrombotic Thrombocytopenic Purpura (Upshaw–Schulman Syndrome): A Comprehensive Disease Characteristics Report

Summary

Congenital thrombotic thrombocytopenic purpura (cTTP), also known as Upshaw–Schulman syndrome (USS) or hereditary TTP (hTTP), is an ultra-rare, life-threatening thrombotic microangiopathy caused by biallelic (homozygous or compound heterozygous) loss-of-function variants in the ADAMTS13 gene on chromosome 9q34.2 (OMIM #274150; gene OMIM *604134). The genetic defect produces severe, lifelong deficiency (typically <10%, often <5–6% activity) of ADAMTS13, the plasma metalloprotease that cleaves von Willebrand factor (VWF). Inheritance is autosomal recessive.

The central pathophysiology is elegantly linear: absent ADAMTS13 protease activity allows ultra-large VWF (UL-VWF) multimers to persist in circulation. Under high shear stress in the microvasculature, these multimers spontaneously bind and aggregate platelets, generating disseminated platelet-rich microthrombi. This produces the clinical triad of consumptive thrombocytopenia, microangiopathic hemolytic anemia (MAHA), and ischemic end-organ injury — most prominently affecting the brain, kidney, and heart. Because ADAMTS13 activity is already at baseline near-zero, additional physiological stressors that raise VWF or shear (birth, pregnancy, infection, inflammation) act as "second hits" that precipitate acute episodes, explaining the marked (~78%) female predominance and the frequent neonatal and pregnancy-associated presentations.

cTTP is a treatable disease when recognized: the therapeutic principle is ADAMTS13 replacement. Historically this was achieved with fresh frozen plasma (FFP) or plasma-derived factor VIII/VWF concentrates that contain ADAMTS13. The field has now been transformed by recombinant ADAMTS13 (apadamtase alfa; Adzynma/TAK-755), which in a pivotal phase 3 crossover trial (NCT03393975) prevented essentially all acute TTP events. This report synthesizes ten confirmed findings across 31 reviewed papers to populate a complete 15-section disease knowledge base entry.

Key Findings

Finding 1 — cTTP is caused by biallelic ADAMTS13 mutations (autosomal recessive)

Congenital TTP results from homozygous or compound heterozygous disease-causing variants in ADAMTS13 (chromosome 9q34.2; OMIM #274150; gene OMIM *604134). The consequence is severe deficiency of the VWF-cleaving metalloprotease, with activity typically <10% and often <5–6%. More than 200 distinct pathogenic variants are distributed across the gene, with missense variants predominating, alongside frameshift, nonsense, and splice-site variants. Inheritance is unambiguously autosomal recessive, meaning both alleles must be affected for disease to manifest.

Foundational evidence comes from Levy and colleagues, who established that "homozygous or compound heterozygous mutations of ADAMTS13 are responsible for recessively inherited TTP" (PMID: 12393505). More recent reviews confirm cTTP is "a rare genetic disorder caused by mutations in the ADAMTS13 gene that leads to decreased or absent production of the plasma von Willebrand factor (VWF)-cleaving metalloprotease ADAMTS13" (PMID: 37895305).

Finding 2 — Pathophysiology: ADAMTS13 deficiency → uncleaved ultra-large VWF → shear-dependent microthrombosis

ADAMTS13 is a ~190 kDa plasma metalloprotease produced mainly by hepatic stellate cells. Its physiological function is to cleave the Tyr1605–Met1606 scissile bond in the VWF A2 domain. Cleavage requires tension/shear-induced unfolding of the A2 domain and allosteric activation of ADAMTS13 through binding of its distal T8–CUB domains to the VWF D4 domain. When ADAMTS13 is deficient, ultra-large VWF multimers accumulate; these spontaneously bind platelets under high shear, producing disseminated microvascular platelet thrombi, consumptive thrombocytopenia, and microangiopathic hemolytic anemia (red cells are mechanically sheared as they pass through partially occluded microvessels).

Crawley and Scully described that "ADAMTS13, a 190-kD plasma protease originating primarily in hepatic stellate cells, prevents microvascular thrombosis by cleaving von Willebrand factor when the substrate is conformationally unfolded by high levels of shear stress" (PMID: 19180123). The precise cleavage site was defined as the "Cleavage of the Tyr(1605)-Met(1606) scissile bond in the VWF A2 domain" (PMID: 17146059).

Finding 3 — Recombinant ADAMTS13 (apadamtase alfa) prevents acute events in phase 3 trial

The pivotal phase 3 open-label crossover trial (NCT03393975; Scully et al., NEJM 2024) enrolled 48 patients randomized to recombinant ADAMTS13 (40 IU/kg IV) versus standard plasma-based prophylaxis. The results were striking: zero acute TTP events occurred during rADAMTS13 prophylaxis versus 1 during standard therapy (mean annualized event rate 0.05). The annualized rate of thrombocytopenia manifestations was 0.74 with rADAMTS13 versus 1.73 with standard therapy. Adverse events occurred in 71% versus 84% of patients respectively, and no anti-ADAMTS13 antibodies developed. The earlier first-in-human phase 1 study (BAX 930) demonstrated dose-proportional pharmacokinetics and good tolerability.

The primary efficacy result was reported as: "No acute TTP event occurred during prophylaxis with recombinant ADAMTS13, whereas 1 patient had an acute TTP event during prophylaxis with standard therapy (mean annualized event rate, 0.05)" (PMID: 38692292). The first-in-human safety was established: "BAX 930 was well tolerated, no serious adverse events occurred, and no anti-ADAMTS-13 antibodies were observed" (PMID: 28912376).

Finding 4 — c.4143dupA (p.Glu1382Argfs) is a Northern/Central European founder mutation

The c.4143dupA (4143insA) frameshift variant in ADAMTS13 exon 29 shows striking geographic concentration in Northern/Central Europe. It has been identified in families from Germany, Norway, Sweden, Poland, the Czech Republic, and Australia (German ancestry). A shared, identical intragenic haplotype across 17 polymorphic markers confirms a common founder origin, making it the single most frequent ADAMTS13 mutation in European cTTP cohorts.

Schneppenheim and colleagues demonstrated that "The haplotypes linked to 4143insA were identical in all informative families" and concluded that "4143insA has a common genetic background and is frequent among patients with hereditary ADAMTS13 deficiency in Northern and Central European countries" (PMID: 16807643).

Finding 5 — Natural history: female predominance, high event rate without prophylaxis, neonatal risk

A retrospective multinational cohort (78 patients, 9 sites) documented that 78.2% of patients were female, with 92 acute TTP events occurring in 70.5% of patients (0.145 events/person-year). Critically, 87% of acute events occurred WITHOUT prophylaxis, and 20% of those unprotected events caused organ damage. Neonatal presentation is common: 35–50% of patients present with severe hemolysis, jaundice, and thrombocytopenia in the first days of life. Pregnancy physiologically lowers ADAMTS13 activity, precipitating relapse, and the International Hereditary TTP Registry documents a clinically heterogeneous course with incomplete genotype-phenotype correlation.

The cohort reported: "Eighty (87.0%) acute TTP events occurred in the absence of prophylactic treatment, of which 16 (20.0%) resulted in organ [damage]" (PMID: 42603082). The neonatal risk was quantified: "The greatest risk for hTTP is in their first days after birth, when 35-50% of patients will have severe hemolysis, jaundice, and thrombocytopenia" (PMID: 38536644).

Finding 6 — Adamts13-knockout mouse requires modifier background + trigger (gene-environment model)

Motto et al. (2005) demonstrated that Adamts13-deficient mice are viable with normal survival but exhibit prolonged VWF-mediated platelet-endothelial interactions. On the CASA/Rk genetic background (which has elevated plasma VWF), a subset develop spontaneous thrombocytopenia and decreased survival. Critically, challenge with shigatoxin produces a syndrome closely resembling human TTP. No correlation was observed between plasma VWF level and TTP severity, implying additional TTP-modifying genes beyond VWF. This is a foundational gene-environment ("two-hit") model of the disease.

The authors reported: "Challenge of these mice with shigatoxin (derived from bacterial pathogens associated with the related human disease hemolytic uremic syndrome) resulted in a striking syndrome closely resembling human TTP" and that "no correlation was observed between plasma vWF level and severity of TTP, implying the existence of TTP-modifying genes distinct from vWF" (PMID: 16200209).

Finding 7 — Pregnancy in cTTP: high loss/morbidity untreated; plasma prophylaxis markedly improves outcomes

Davidesko et al. (2023) studied a cohort of 14 women with hTTP (homozygous c.3772delA) across 71 pregnancies: 17 (24%) ended in pregnancy loss and 32 (45%) were complicated by severe obstetric morbidity (SOM). FFP-treated pregnancies had dramatically lower SOM (28% vs 72%, p<0.001) and fewer preterm TTP exacerbations (18% vs 82%, p<0.001). Elevated non-pregnant VWF antigen predicted SOM even among treated women (225% vs 165%, p=0.047), suggesting VWF antigen may be a useful biomarker. In a separate case, recombinant ADAMTS13 rescued a plasma-refractory pregnancy, leading to a live birth.

The benefit of prophylaxis was quantified: "Treated women had decreased SOM (28% vs 72%, p < .001) and preterm thrombotic thrombocytopenic purpura exacerbations (18% vs 82%, p < .001)" (PMID: 36889591). The recombinant rescue case reported: "weekly injections of recombinant ADAMTS13 at a dose of 40 U per kilogram of body weight were initiated. The patient's platelet count normalized" (PMID: 36546627).

Finding 8 — ADAMTS13 circulates in a closed (autoinhibited) conformation opened allosterically by VWF

Plasma ADAMTS13 circulates in a folded/closed conformation stabilized by an intramolecular interaction between the central Spacer domain and the C-terminal CUB domains. Binding of the distal domains to VWF D4(-CK), or to activating antibodies, extends ADAMTS13 into an open, catalytically enhanced conformation, increasing the metalloprotease-domain kcat approximately 2-fold and exposing a cryptic epitope in the metalloprotease domain. Flexible linker regions around the metalloprotease and T2 domains mediate this conformational activation. This closed-to-open allosteric switch is central to understanding both physiology and engineered therapeutics.

Schelpe et al. established that "Plasma ADAMTS13 circulates in a folded conformation that is stabilized by an interaction between the central Spacer domain and the C-terminal CUB" and that "conformational extension of ADAMTS13 enhances the proteolytic function of the metalloprotease domain (kcat), rather than augmenting substrate binding (Km)" (PMID: 32196558). Deforche et al. identified the linker regions responsible for this flexibility (PMID: 26391536).

Finding 9 — Diagnosis relies on ADAMTS13 activity <10% (FRETS-VWF73 gold standard)

TTP is defined by severe ADAMTS13 activity deficiency (<10%). The FRETS-VWF73 fluorogenic assay is the reference/gold-standard method. The automated chemiluminescent immunoassay HemosIL AcuStar is faster but shows clinically relevant discrepancies versus FRETS-VWF73 (affecting diagnosis in 5/32 and follow-up in 7/51 samples; AcuStar reads systematically lower), partly because autoantibodies reduce activity more in AcuStar/ELISA than in FRETS assays. Novel fiber-optic surface plasmon resonance (FO-SPR) assays (detection limit ~6.8%, CV 7.2%) are in development. For cTTP specifically, absence of an anti-ADAMTS13 inhibitor plus biallelic pathogenic ADAMTS13 variants confirms the congenital form and distinguishes it from the acquired/immune form (iTTP).

Evidence documents that "discrepancies between AcuStar and the gold standard FRETS-VWF73 have been documented in a manner that would affect diagnosis and treatment" (PMID: 37063760) and that "Thrombotic thrombocytopenic purpura (TTP) is characterized by severe ADAMTS-13 activity deficiency (<10%)" (PMID: 37711907).

Finding 10 — Residual-activity variants (e.g., R1060W) cause late-onset/pregnancy-triggered cTTP

Falter et al. (2014) reported a patient with compound heterozygous ADAMTS13 p.Q44X (exon 2 premature stop) plus p.R1060W (exon 24 missense associated with low but measurable ADAMTS13 activity), who presented as late-onset, pregnancy-induced cTTP — first acute episode at age 19 during a first pregnancy, with a sibling who died during a second pregnancy. R1060W is a recurrent variant enriched among adult/pregnancy-onset patients. Registry data similarly show that higher residual ADAMTS13 activity correlates with later overt disease onset — a genotype-phenotype relationship of clinical importance.

The authors described "a missense mutation in exon 24 (p.R1060W) associated with low but measurable ADAMTS13 activity" and emphasized that "Genetic analysis of the ADAMTS13 gene is important in TTP patients of all ages if an ADAMTS13 inhibitor has been excluded" (PMID: 24994604).

Comprehensive Disease Profile (15 Sections)

1. Disease Information

Overview. Congenital thrombotic thrombocytopenic purpura is an ultra-rare, autosomal-recessive thrombotic microangiopathy caused by inherited severe deficiency of ADAMTS13. It manifests as episodic microvascular thrombosis producing thrombocytopenia, microangiopathic hemolytic anemia, and ischemic organ damage.

Key identifiers: | Resource | Identifier | |----------|-----------| | OMIM (disease) | #274150 | | OMIM (gene) | *604134 (ADAMTS13) | | Suggested MONDO | MONDO:0010134 (congenital TTP / Upshaw–Schulman syndrome) | | ICD-10 | D69.4 / M31.1 (thrombotic microangiopathy grouping) | | ICD-11 | 3B64.1 (thrombotic microangiopathy) | | MeSH | Purpura, Thrombotic Thrombocytopenic (D011697) | | Orphanet | ORPHA:93583 (hereditary/congenital TTP) | | Gene locus | 9q34.2 |

Synonyms: Upshaw–Schulman syndrome (USS); hereditary TTP (hTTP); congenital TTP (cTTP); familial TTP; ADAMTS13 deficiency, congenital.

Information source type: Predominantly derived from aggregated disease-level resources — the International Hereditary TTP Registry, multinational retrospective cohorts, and case series — rather than population-scale EHR, reflecting its ultra-rare status.

2. Etiology

Primary cause: Genetic — biallelic loss-of-function variants in ADAMTS13 (Finding 1). This is the necessary and sufficient molecular cause of the congenital form.

Genetic risk factors: The causal variants themselves (>200 known pathogenic variants). Founder alleles increase population-specific risk, notably c.4143dupA/p.Glu1382Argfs in Northern/Central Europe (Finding 4). Modifier genes beyond ADAMTS13 modulate severity — the mouse model demonstrated TTP-modifying genes distinct from VWF (Finding 6). Common ADAMTS13 amino-acid polymorphisms (R7W, Q448E, P618A, A732V) can act as positive or negative modifiers of secretion/activity depending on context (PMID: 16160007).

Environmental / triggering risk factors: Pregnancy (physiologically lowers ADAMTS13 and raises VWF), the neonatal period/birth, infection and inflammation, and surgery. Female sex is a major demographic risk factor (~78% of patients) driven largely by pregnancy-triggered episodes (Finding 5).

Protective factors: No specific genetic protective alleles are established. The dominant modifiable protective factor is prophylactic ADAMTS13 replacement (plasma or recombinant), which prevented 87% of the acute events that occurred in its absence (Findings 5, 7).

Gene-environment interactions: The disease is a paradigm of gene-environment ("two-hit") interaction — an underlying genetic ADAMTS13 deficiency requires an environmental/physiological trigger (elevated VWF/shear) to precipitate overt disease. This is directly demonstrated in the Adamts13-knockout mouse, which develops TTP only on a high-VWF background AND after shigatoxin challenge (Finding 6).

3. Phenotypes

Characteristics. Onset ranges from neonatal (35–50%) through childhood to adult/pregnancy-triggered late onset. Severity is variable and partly genotype-dependent — residual-activity alleles (R1060W) associate with milder, later-onset disease (Finding 10). The course is characteristically episodic/relapsing, punctuated by triggers. Quality-of-life impact is substantial: recurrent hospitalizations, need for regular infusions, pregnancy loss and obstetric morbidity, and risk of permanent stroke- or renal-related disability.

4. Genetic/Molecular Information

Causal gene: ADAMTS13 (HGNC:1366; gene OMIM *604134; 9q34.2), encoding the VWF-cleaving metalloprotease.

Pathogenic variants: >200 distinct variants distributed across all domains; missense predominate, with frameshift, nonsense, and splice-site variants also common (Finding 1). Classification per ACMG/AMP spans pathogenic and likely pathogenic; residual-activity missense alleles may be VUS pending functional data. Representative variants: c.4143dupA (p.Glu1382Argfs) — European founder frameshift; p.R1060W — residual-activity missense enriched in adult/pregnancy onset; p.Q44X — nonsense; c.3772delA and c.721delG (p.Gly241fs) — frameshift; p.R1336W and p.P618A — activity-reducing missense. Variants are germline (not somatic). Functional consequence is predominantly loss of function (impaired secretion and/or catalytic activity).

Modifier genes: Motto et al. established the existence of TTP-modifying genes distinct from VWF (Finding 6). Intragenic ADAMTS13 polymorphisms modulate secretion/activity (PMID: 16160007).

Epigenetic information / chromosomal abnormalities: No disease-defining epigenetic changes or large-scale chromosomal abnormalities are established for cTTP; it is a single-gene monogenic disorder.

5. Environmental Information

Environmental / lifestyle factors: cTTP is not caused by environmental toxins, radiation, or lifestyle. However, physiological/environmental triggers unmask disease: pregnancy, birth, infection, inflammation, and surgery.

Infectious agents: No pathogen causes cTTP. Notably, shigatoxin (from Shiga-toxin–producing bacteria, classically associated with HUS) triggers a TTP-like syndrome in genetically susceptible ADAMTS13-deficient mice, illustrating how infection can serve as an environmental "second hit" (Finding 6).

6. Mechanism / Pathophysiology

Causal chain (upstream → downstream):

Biallelic ADAMTS13 LoF variants (germline)
        │
        ▼
Severe deficiency of ADAMTS13 metalloprotease activity (<10%)
        │
        ▼
Failure to cleave VWF A2 domain (Tyr1605–Met1606 scissile bond)
        │
        ▼
Persistence of ultra-large VWF (UL-VWF) multimers
        │
        ▼  (TRIGGER: high shear / ↑VWF from pregnancy, infection, birth)
Spontaneous UL-VWF–platelet binding under shear
        │
        ▼
Disseminated platelet-rich microthrombi in microvasculature
        │
        ├──► Platelet consumption → THROMBOCYTOPENIA
        ├──► RBC mechanical shearing → MICROANGIOPATHIC HEMOLYTIC ANEMIA
        └──► Microvascular occlusion → ISCHEMIC ORGAN INJURY (brain, kidney, heart)

Molecular pathway / cellular processes: Hemostasis — VWF-dependent platelet adhesion and aggregation (GO:0007596 blood coagulation; GO:0070527 platelet aggregation). Proteolysis (GO:0006508) by the metalloprotease.

Protein dysfunction: Loss of function via impaired secretion, misfolding, truncation, or reduced catalytic activity. The wild-type enzyme is regulated by a closed→open allosteric conformational switch (Spacer–CUB autoinhibition relieved by VWF-D4 binding, ~2-fold kcat increase; Finding 8). Missense variants can disrupt secretion, catalysis, or allosteric regulation.

Suggested GO/CL/CHEBI terms: GO:0004222 (metalloendopeptidase activity), GO:0005576 (extracellular region); CL:0000232 (erythrocyte), CL:0000233 (platelet), CL:0002679 (hepatic stellate cell), CL:0000115 (endothelial cell); CHEBI:29108 (calcium, cofactor), CHEBI:18420 (zinc, catalytic metal).

7. Anatomical Structures Affected

Damage is bilateral and diffuse (microvascular), not focal or lateralized.

8. Temporal Development

Onset: Congenital deficiency present from birth; clinical onset ranges from neonatal (35–50% present in first days of life with hemolysis, jaundice, thrombocytopenia) through childhood to adult/pregnancy-triggered late onset (Findings 5, 10). Onset pattern of acute episodes is acute/subacute.

Progression: The disease course is episodic/relapsing-remitting overlaid on a chronic, lifelong deficiency state. Acute events cluster around triggers. Progression rate is variable and partly determined by residual ADAMTS13 activity — higher residual activity correlates with later overt onset (Findings 5, 10).

Patterns: Remission is treatment-induced (prophylactic replacement) between episodes; there is no spontaneous cure. Critical vulnerability windows are the neonatal period and pregnancy, which are also the key windows for prophylactic intervention.

9. Inheritance and Population

Epidemiology: Ultra-rare. Estimated prevalence on the order of ~1–2 per million (cTTP accounts for a minority of all TTP; overall TTP incidence ~1.5–6 per million/year). Orphanet classifies it among ultra-rare disorders.

Genetic parameters: - Inheritance: Autosomal recessive (Finding 1). - Penetrance: High at the biochemical level (biallelic LoF → severe deficiency), but clinical penetrance/expressivity is variable and incomplete — the registry documents heterogeneous course and imperfect genotype-phenotype correlation (PMID: 30792199). - Expressivity: Variable, modulated by residual activity, modifier genes, and triggers. - Founder effects: c.4143dupA in Northern/Central Europe (Finding 4). - Consanguinity: Increases homozygous cases in populations with high consanguinity. - Genetic anticipation / mosaicism: Not applicable / not established.

Demographics: Marked female predominance (~78%), driven by pregnancy-triggered presentation (Finding 5). Affects all ethnicities; specific founder variants show geographic clustering (European c.4143dupA). Age distribution is bimodal-ish: neonatal peak and a young-adult female (pregnancy) peak.

10. Diagnostics

Core laboratory diagnosis: Severe ADAMTS13 activity <10% measured by the gold-standard FRETS-VWF73 fluorogenic assay (Finding 9). Supportive labs: thrombocytopenia, MAHA with schistocytes on smear, elevated LDH, low haptoglobin, elevated indirect bilirubin, negative direct antiglobulin test.

Distinguishing cTTP from iTTP: In cTTP, an anti-ADAMTS13 inhibitor/autoantibody is ABSENT and biallelic pathogenic ADAMTS13 variants are present. In acquired iTTP, an inhibitor is present (Finding 9). Mixing studies and anti-ADAMTS13 IgG assays help discriminate.

Genetic testing: ADAMTS13 single-gene sequencing (or gene panels including complement genes for TMA differential; PMID: 30046676) is definitive. Genetic analysis is recommended in TTP patients of all ages once an inhibitor is excluded (Finding 10). WES/WGS are useful when panels are non-diagnostic. Chromosomal microarray/karyotype/FISH are not indicated (single-gene disorder).

Emerging assays: HemosIL AcuStar (faster, but reads systematically lower, with diagnostic discrepancies) and fiber-optic SPR immunoassays (Finding 9).

Differential diagnosis: Acquired iTTP; atypical HUS (complement dysregulation); Shiga-toxin HUS; DIC; HELLP/pregnancy TMA; Evans syndrome; immune thrombocytopenia (ITP) — the latter is a recognized misdiagnosis before hTTP is revealed by pregnancy loss (PMID: 39614241).

11. Outcome/Prognosis

Mortality/morbidity: Untreated acute events are life-threatening; historically high mortality. The dominant modifiable determinant of outcome is prophylaxis — 87% of acute events occurred without prophylaxis, and 20% of those caused organ damage (Finding 5). Recurrent strokes and chronic kidney damage drive long-term morbidity and disability.

Life expectancy: With appropriate ADAMTS13 replacement prophylaxis, acute events are largely preventable and long-term outlook is substantially improved; without it, recurrent life-threatening episodes and cumulative ischemic organ damage occur.

Pregnancy outcomes: Untreated pregnancies carry high risk — 24% loss and 45% severe obstetric morbidity in one cohort; plasma prophylaxis reduces SOM to 28% (from 72%) (Finding 7).

Prognostic factors/biomarkers: Residual ADAMTS13 activity (higher = later/milder onset; Findings 5, 10); adherence to prophylaxis; and elevated non-pregnant VWF antigen predicts severe obstetric morbidity (Finding 7) — a candidate prognostic biomarker.

12. Treatment

Principle: ADAMTS13 replacement.

Recombinant ADAMTS13 is now the transformative therapy (Finding 3): 40 IU/kg IV, prophylaxis prevented essentially all acute events with a favorable safety profile and no anti-ADAMTS13 antibody development. It also rescued a plasma-refractory pregnancy (Finding 7).

Emerging/experimental: ADAMTS13 gene therapy; additional recombinant products; and novel VWF-activity inhibitors are under development (PMID: 42422077). A constitutively active ADAMTS13 variant (Ala1144Val, "caADAMTS13") with ~5-fold enhanced activity shows thrombolytic/anti-inflammatory efficacy in murine stroke models (PMID: 34780600).

Supportive care: Individualized infusion intervals guided by ADAMTS13 activity or, where testing is limited, surrogate markers (platelet count, LDH). Therapeutic plasma exchange can prolong intervals between administrations in some patients (PMID: 30394580).

13. Prevention

• Primary prevention: Not applicable (genetic disease); genetic counseling and carrier screening in affected families and consanguineous populations.
• Secondary prevention: Early diagnosis via ADAMTS13 testing and genetic confirmation; neonatal vigilance in known-carrier families.
• Tertiary prevention (core strategy): Prophylactic ADAMTS13 replacement to prevent acute events and organ damage — especially intensified during pregnancy and the peripartum period (Findings 5, 7). Regimen individualization (e.g., FFP every 10 days intensified to weekly in third trimester) enables successful full-term pregnancy even in resource-limited settings (PMID: 42529691).
• Counseling: Genetic counseling for family planning, prenatal/carrier testing, and pregnancy management planning.

14. Other Species / Natural Disease

• Taxonomy/orthologs: ADAMTS13 is conserved across vertebrates. Mouse Adamts13 (NCBI Gene) is the principal experimental ortholog. Phylogenetic analysis across 264 vertebrates shows allosteric regulation of ADAMTS13 is broadly conserved across placental mammals, birds, and amphibians (PMID: 30700419).
• Natural disease / veterinary relevance: No well-established naturally occurring cTTP-equivalent is prominently documented in companion animals in the reviewed literature; the disease is chiefly modeled experimentally (see Section 15).
• Evolutionary conservation: The T7 and T8 distal domains are essential for allosteric activation, while T3–T6 are dispensable and have been repeatedly deleted across lineages, indicating conserved core mechanism with flexible peripheral architecture (PMID: 30700419).

15. Model Organisms

Principal model — Adamts13-knockout mouse (Motto et al. 2005): - Type: Mammalian genetic knockout. - Phenotype recapitulation: Partial — mice are viable with normal survival and prolonged VWF-platelet-endothelial interactions but do not spontaneously develop full TTP on a standard background. On the CASA/Rk high-VWF background, a subset develop spontaneous thrombocytopenia; shigatoxin challenge produces a syndrome closely resembling human TTP (Finding 6). - Value: Demonstrates the essential gene-environment ("two-hit") architecture and the existence of TTP-modifying genes beyond VWF. - Limitation: Requires modifier background plus trigger; does not capture the full spontaneous human phenotype in isolation.

Engineered variant models: The constitutively active caADAMTS13 (Ala1144Val) used in murine stroke models illustrates therapeutic proof-of-concept for conformationally activated enzyme (PMID: 34780600).

Applications: Studying VWF-ADAMTS13 axis, trigger biology, thrombolytic/therapeutic testing, and gene-therapy development.

Resources: MGI (mouse Adamts13), IMPC/KOMP for knockout resources.

Mechanistic Model / Interpretation

The unifying model of cTTP is a single-enzyme deficiency with an amplifying, trigger-dependent thrombotic cascade. ADAMTS13 is the sole physiological regulator of VWF multimer size. Its congenital absence is necessary but often not sufficient for overt disease — the near-zero baseline activity creates a "primed" state in which the addition of high shear or elevated VWF (from pregnancy, birth, infection, or inflammation) tips the balance toward runaway VWF-platelet microthrombosis. This explains three otherwise puzzling clinical observations: (1) the marked female predominance (pregnancy is the archetypal trigger), (2) the neonatal-birth vulnerability window, and (3) the variable, episodic course despite a fixed genetic lesion.

The allosteric biology of ADAMTS13 (closed-Spacer/CUB autoinhibition relieved by VWF-D4 binding) is not merely mechanistic detail — it directly informs therapeutics. Understanding that catalytic output is governed by a conformational switch enabled engineering of constitutively active variants with enhanced thrombolytic potency, and it clarifies why recombinant enzyme replacement so effectively restores the missing regulatory function.

The genotype-phenotype relationship is best understood as a continuum of residual activity: null/severe alleles (frameshift, nonsense, founder c.4143dupA) tend toward neonatal/childhood onset, while residual-activity missense alleles (R1060W) permit late, trigger-dependent (pregnancy) presentation. This is coherent with the registry finding that higher residual ADAMTS13 activity predicts later overt onset.

Therapeutically, the disease has moved from a reactive, plasma-based paradigm to proactive recombinant ADAMTS13 prophylaxis, which in the pivotal trial reduced acute events essentially to zero. The natural-history data — that 87% of acute events occur without prophylaxis — provide the quantitative rationale for lifelong prophylactic replacement.

Evidence Base

Limitations and Knowledge Gaps

1. Epidemiology precision. Exact prevalence/incidence of the congenital form is uncertain due to under-diagnosis and misclassification (e.g., misdiagnosis as ITP). Reported figures are estimates from registries and cohorts, not population-scale surveillance.
2. Incomplete genotype-phenotype correlation. The registry explicitly documents heterogeneity that residual-activity alone does not fully explain; modifier genes beyond VWF are implicated by the mouse model but not fully mapped in humans.
3. Long-term outcomes of recombinant ADAMTS13. The phase 3 trial establishes short/medium-term efficacy and safety; long-term (multi-decade) organ-protection, immunogenicity, and pregnancy-cohort data are still accruing.
4. Biomarker validation. VWF antigen as a predictor of obstetric morbidity is promising but from a single small cohort and needs prospective validation.
5. Animal model fidelity. No single model spontaneously recapitulates the full human episodic phenotype without engineered modifier backgrounds and triggers.
6. Gene therapy is preclinical/early. Curative approaches remain investigational.

Proposed Follow-up Experiments / Actions

1. Prospective natural-history registry expansion with standardized ADAMTS13 activity (FRETS-VWF73) and genotype capture to refine genotype–residual-activity–onset relationships and to validate VWF antigen as a prognostic biomarker.
2. Long-term (5–10 year) follow-up of recombinant ADAMTS13 cohorts, including pregnancy sub-studies, immunogenicity surveillance, and organ-protection (renal/neurologic) endpoints.
3. Modifier-gene mapping in humans (GWAS/WGS in registry cohorts) to identify the TTP-modifying loci predicted by the CASA/Rk mouse studies.
4. Advance ADAMTS13 gene therapy from preclinical models toward first-in-human trials, leveraging the well-defined single-gene target and hepatic stellate-cell/hepatocyte expression biology.
5. Standardize/harmonize ADAMTS13 activity assays to resolve AcuStar vs FRETS-VWF73 discrepancies and validate rapid point-of-care assays (FO-SPR) for acute diagnosis.
6. Structure-guided next-generation enzymes — evaluate constitutively active (open-conformation) ADAMTS13 variants for acute event termination and potentially reduced dosing frequency.
7. Pregnancy-management trials comparing recombinant ADAMTS13 versus plasma prophylaxis regimens with maternal-fetal outcome endpoints.

Report compiled from 10 confirmed findings across 5 investigation iterations and 31 reviewed papers. Evidence types span human RCT, human cohort/registry, human case reports, in vitro/structural, comparative/phylogenetic, and model-organism studies.